NasdaqGM · Biotechnology

NewAmsterdam Pharma Company NV (NAMS)

Stock, pipeline and biotech catalyst intelligence

Analyst view

Buy+86.4%

$51.95 average target

$27.87+0.09 (+0.3%)Latest market snapshot · Yahoo Finance

Market cap$3.26B

Cash$633.9M

Quarterly burn$39.2M

Pipeline assets8

Short float9.9%

Market expectations

Analyst Ratings & Price Targets

Data may be delayed

Street view at a glance

The average target implies 86.4% upsideTargets are estimates—not guarantees—and can change after company updates.

$51.95Average target

Wall Street consensus

BuyCalculated from 16 current ratings

16ratings

Buy 15Hold 1Sell 0

Price-target range

$51.95

+86.4%

Low $38.44High $60.69

CurrentAverage

Bear case$38.44+37.9%

Base case$51.95+86.4%

Bull case$60.69+117.7%

Analyst coverage15published opinions

Bullish share94%buy recommendations

Target spread$22low-to-high dispersion

Consensus score—1.0 is strongest

Recommendation mix

Current rating breakdown

16 tracked ratings

Company profile

About NewAmsterdam Pharma Company NV

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

Company profile supplied by Yahoo Finance. Catalyst dates can change and should be confirmed against the linked primary source.

Page updated Aug 21, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.